Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy
Fibrosis assessment is an important prognostic indicator and clinical trial endpoint in metabolic dysfunction-associated steatotic liver disease, but liver biopsy sampling variation quality assurance has not been investigated for second-harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy quantification of fibrosis. Longer (>20 mm) and wider (>0.9 mm) biopsies allow for more accurate digital assessment of fibrosis. Clinical trials should incorporate suitable protocols to verify biopsy sizes that optimise digital fibrosis assessment using SHG/TPEF.
Authors
- David E. Kleiner (ORCID: https://orcid.org/0000-0003-3442-4453)
- Yayun Ren (ORCID: https://orcid.org/0000-0002-8613-5728)
- Elaine Chng (ORCID: https://orcid.org/0009-0007-8535-2281)
- Nikolai V. Naoumov (ORCID: https://orcid.org/0009-0009-3091-4990)
- Kutbuddin Akbary
- Arun Jayant Sanyal (ORCID: https://orcid.org/0000-0001-8682-5748)
- Dean Tai (ORCID: https://orcid.org/0000-0002-6166-5618)
- Timothy James Kendall (ORCID: https://orcid.org/0000-0002-4174-2786)
- Jonathan Andrew Fallowfield (ORCID: https://orcid.org/0000-0002-5741-1471)
- D Field (ORCID: https://orcid.org/0000-0001-7505-6584)
Institutions
- National Institutes of Health (US)
- Virginia Commonwealth University (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Centre for Inflammation Research (GB)
- Histoindex (Singapore) (SG)
- University College London (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101449
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline
- Genentech
- Innovate UK
- Eurostars